Standards of medical care for type 2 diabetes in China 2019

W Jia, J Weng, D Zhu, L Ji, J Lu, Z Zhou… - Diabetes/metabolism …, 2019 - Wiley Online Library
The prevalence of diabetes in China has increased rapidly from 0.67% in 1980 to 10.4% in
2013, with the aging of the population and westernization of lifestyle. Since its foundation in …

Effects of medications on heat loss capacity in chronic disease patients: health implications amidst global warming

J Wee, XR Tan, SH Gunther, M Ihsan, MKS Leow… - Pharmacological …, 2023 - Elsevier
Pharmacological agents used to treat or manage diseases can modify the level of heat strain
experienced by chronically ill and elderly patients via different mechanistic pathways …

Артериальная гипертензия у взрослых. Клинические рекомендации 2020

ЖД Кобалава, АО Конради, СВ Недогода… - Российский …, 2020 - cyberleninka.ru
Члены Рабочей группы: Арутюнов ГП, Баранова ЕИ, Барбараш ОЛ, Бойцов СА,
Вавилова ТВ, Виллевальде СВ, Галявич АС, Глезер МГ, Гринева ЕН, Гринштейн ЮИ …

Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn's Registry

G Hanslik, H Wallaschofski, A Dietz… - European Journal of …, 2015 - academic.oup.com
Abstract Design Abnormalities in glucose homeostasis have been described in patients with
primary aldosteronism (PA) but most studies show inconsistent results. Therefore, we aimed …

Beneficial effects of Angiotensin II receptor blockers in brain disorders

JM Saavedra - Pharmacological research, 2017 - Elsevier
A canonical brain Renin-Angiotensin System (RAS), like the canonical peripheral RAS, has
long been proposed as a major regulator of brain function. Because of methodological …

[HTML][HTML] Коморбидность пациентов с хроническими неинфекционными заболеваниями в практике врача-терапевта. Евразийское руководство

ОМ Драпкина, АВ Концевая, АМ Калинина… - Кардиоваскулярная …, 2024 - cyberleninka.ru
[Драпкина ОМ—д. м. н., профессор, академик РАН, главный внештатный специалист
Минздрава по терапии и общей врачебной практике, директор, ФГБУ" НМИЦ ТПМ" …

Effects and safety of a novel oral potassium-lowering drug-sodium zirconium cyclosilicate for the treatment of hyperkalemia: a systematic review and meta-analysis

Y Zhang, R Xu, F Wang, Y Liu, J Xu, N Zhao… - … Drugs and Therapy, 2021 - Springer
Background Oral sodium zirconium cyclosilicate (SZC) is a novel potassium binder capable
of achieving a rapid reduction of serum potassium (sK+) and maintaining a long-term …

[HTML][HTML] National Heart Center/Saudi Heart Association 2023 guidelines on the management of hypertension

W Alhabeeb, AA Tash, M Alshamiri… - Journal of the Saudi …, 2023 - ncbi.nlm.nih.gov
National Heart Center/Saudi Heart Association 2023 Guidelines on the Management of
Hypertension - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …

Cardiovascular disease prevention strategies for type 2 diabetes mellitus

N Katsiki, F Purrello, C Tsioufis… - Expert Opinion on …, 2017 - Taylor & Francis
Introduction: Type 2 diabetes mellitus (T2DM) is associated with several cardiovascular (CV)
risk factors such as insulin resistance, obesity, hypertension, dyslipidaemia, non-alcoholic …

Angiotensin enzyme inhibitors and angiotensin receptor blockers as protective factors in COVID-19 mortality: a retrospective cohort study

A Yahyavi, N Hemmati, P Derakhshan… - Internal and emergency …, 2021 - Springer
Targeting the renin-angiotensin system is proposed to affect mortality due to coronavirus
disease 2019 (COVID-19). We aimed to compare the mortality rates in COVID-19 patients …